by Swiss Approval | 24 June 2024 | Urogenital
In recent developments within the field of oncology, several new treatment options have received approval, offering fresh hope for patients battling various forms of cancer. These approvals highlight the advancements in targeted therapies and the ongoing commitment to...
by FDA Approval | 14 June 2024 | Solid Tumors
The FDA has granted accelerated approval to repotrectinib for the treatment of adult and pediatric patients aged 12 years and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion. This approval targets patients with locally...
by FDA Approval | 13 June 2024 | Solid Tumors
The FDA has approved selpercatinib for both adults and pediatric patients who are 2 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory. This approval comes...
by EMA Approval | 7 June 2024 | Lung Cancer
The FDA and the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) have approved or recommended a wave of new drugs that are set to transform cancer treatment. These approvals span across various oncological areas, including...
